ClinicalTrials.gov
ClinicalTrials.gov Menu

Insulinotropic Effect of GIP and GLP-1 Before and After Reduced Glucose Tolerance

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01173978
Recruitment Status : Completed
First Posted : August 3, 2010
Last Update Posted : June 21, 2011
Sponsor:
Collaborators:
University of Copenhagen
European Foundation for the Study of Diabetes
Information provided by:
Glostrup University Hospital, Copenhagen

Brief Summary:
The incretin effect in patients with type two diabetes is reduced. The investigators have previously shown that it is possible to induce a defect in the incretin effect in healthy individuals. The purpose of this study is to evaluate the insulinotropic affect of the incretin hormones in healthy individuals before and after a deterioration of the glucose homeostasis.

Condition or disease Intervention/treatment Phase
Insulin Resistance Deteriorated Glucose Homeostasis Inactivity Behavioral: Steroid hormone Other: No intervention Not Applicable

Detailed Description:
The incretin effect in patients with type two diabetes is reduced. The investigators have previously shown that it is possible to induce a defect in the incretin effect in healthy individuals. The purpose of this study is to evaluate the insulinotropic affect of the incretin hormones in healthy individuals before and after a deterioration of the glucose homeostasis. The evaluation is done by infusing GIP, GLP-1 or saline during hyperglycemic clamps.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: Insulinotropic Effect of GIP and GLP-1 Before and After Reduced Glucose Induced by Steroid Treatment, Relative Physical Inactivity and High Calorie Diet
Study Start Date : April 2010
Actual Primary Completion Date : July 2010
Actual Study Completion Date : July 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hormones

Arm Intervention/treatment
Experimental: No intervention
Each participant is examined during a normal, active lifestyle, without any intervention: The examinations include an OGTT, a glucagon test, three hyperglycemic clamps with infusion of a)GLP-1; b)GIP; c)Nacl
Other: No intervention
Experimental: Intervention
Each participant is examined during a 12 days intervention.The examinations include an OGTT, a glucagon test, three hyperglycemic clamps with infusion of a)GLP-1; b)GIP; c)Nacl
Behavioral: Steroid hormone
Steroid hormone: 37,5 mg of prednisolone; High energy diet: 130 % of recommended daily energy intake; Relative physical inactivity: no exercise and at least 8 hours of rest/day
Other Name: Prednisolone




Primary Outcome Measures :
  1. Insulinotropic effect of incretin hormones [ Time Frame: 12 days ]
    Measurements of the insulinotropic effect of incretin hormones before and after 12 days intervention with steroid treatment, high calorie diet and relative physical inactivity


Secondary Outcome Measures :
  1. Plasma concentration of glucagon [ Time Frame: 12 days ]
    Measurements of plasma concentration of glucagon before and after 12 days intervention with steroid treatment, high calorie diet and relative physical inactivity



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Caucasians without type 2 diabetes mellitus
  • Normal OGTT (75 g of glucose) according to WHO's criteria
  • BMI 20-30
  • Hemoglobin > 8.0 mmol/l
  • Informed consent

Exclusion Criteria:

  • Liver disease (ALAT > 2 x normal level)
  • Nephropathy (s-creatinin > 130 µM or albuminuria)
  • Relatives (parents/siblings) with T2DM
  • Medical treatment witch cannot be stopped for 12 hours

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01173978


Locations
Denmark
Department of Clinical Physiology
Glostrup, Denmark, DK-2600
Sponsors and Collaborators
Glostrup University Hospital, Copenhagen
University of Copenhagen
European Foundation for the Study of Diabetes
Investigators
Principal Investigator: Katrine B Hansen, MD Glostrup University Hospital
Study Chair: Filip K Knop, MD,PhD Gentofte University Hospital
Study Chair: Tina Vilsbøll, MD,DmSc Gentofte University Hospital
Study Chair: Jens J Holst, MD, DmSc University of Copenhagen

Responsible Party: Katrine Bagge Hansen. MD, Glostrup University Hospital
ClinicalTrials.gov Identifier: NCT01173978     History of Changes
Other Study ID Numbers: DYS-CLAMP
First Posted: August 3, 2010    Key Record Dates
Last Update Posted: June 21, 2011
Last Verified: July 2010

Keywords provided by Glostrup University Hospital, Copenhagen:
Incretin hormones
Glucagon
Insulin/c-peptide
Plasma glucose
Insulin resistance
Deteriorated glucose homeostasis
Inactivity

Additional relevant MeSH terms:
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Hormones
Prednisolone
Methylprednisolone
Methylprednisolone Hemisuccinate
Prednisolone hemisuccinate
Prednisolone phosphate
Glucagon
Prednisolone acetate
Methylprednisolone acetate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Inflammatory Agents
Glucocorticoids
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Neuroprotective Agents
Protective Agents